REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

This study is investigating whether patients with chronic lymphocytic leukemia (CLL) who previously completed a time-limited course of venetoclax (a targeted cancer drug) and then relapsed can benefit from retreatment with venetoclax, this time combined with acalabrutinib. **You may be eligible if...** - You have CLL or small lymphocytic lymphoma (SLL) that requires treatment again - You previously received venetoclax as part of a specific clinical study (HOVON 139 or HOVON 140) and had at least a partial response - Your disease has now relapsed and meets standard criteria for retreatment - You are in reasonably good health (ECOG 0-3) **You may NOT be eligible if...** - You have certain genetic mutations that may make treatment less effective - You have significant organ dysfunction - You developed serious complications from prior venetoclax treatment Talk to your doctor to see if this trial is right for you.